Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.
Dermatology and Therapy|January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge StudyJeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
The American Journal of Cardiology|December 10, 2008
AJC editor's consensus: psoriasis and coronary artery diseaseVincent E Friedewald, Jennifer C Cather, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsAlan Menter, Alice Gottlieb, Steven R Feldman, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsAlice Gottlieb, Neil J Korman, Kenneth B Gordon, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.
Dermatology and Therapy|January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge StudyJeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
The American Journal of Cardiology|December 10, 2008
AJC editor's consensus: psoriasis and coronary artery diseaseVincent E Friedewald, Jennifer C Cather, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsAlan Menter, Alice Gottlieb, Steven R Feldman, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsAlice Gottlieb, Neil J Korman, Kenneth B Gordon, et al.
Pageof 14